menu
    • menu
    [{"orgOrder":0,"company":"Nemysis","sponsor":"Avia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Financing","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nemysis \/ Avia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nemysis \/ Avia Pharma"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ European Union"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nemysis \/ Bruno Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Nemysis \/ Bruno Farmaceutici"},{"orgOrder":0,"company":"Nemysis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nemysis \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nemysis

    Menu

    Nemysis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iron Hydroxide Adipate Tartrate

    Therapeutic Area : Hematology

    Study Phase : Phase III

    Sponsor : Avia Pharma

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    Nemysis Limited Announces Investment by Avia Pharma AB in the Capital of the Company

    Details : The financing aims to fund the clinical development of IHAT (iron hydroxide adipate tartrate), which is being evaluated for the treatment of iron deficiency.

    Product Name : IHAT

    Product Type : Vitamins/Minerals/Inorganic Salts

    Upfront Cash : Undisclosed

    March 18, 2025

    Lead Product(s) : Iron Hydroxide Adipate Tartrate

    Therapeutic Area : Hematology

    Highest Development Status : Phase III

    Sponsor : Avia Pharma

    Deal Size : Undisclosed

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Endoprotease 40 Glutenase

    Therapeutic Area : Gastroenterology

    Study Phase : Phase I

    Sponsor : European Union

    Deal Size : $2.7 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Nemysis Limited Receives EU Horizon Grant Funding for E40

    Details : The net proceeds will fund the completion of research & development to Market Authorization of Nemysis' novel E40 (endoprotease 40 glutenase) for the prevention of symptomatic gluten exposure in gluten intolerance and sensitivity.

    Product Name : E40

    Product Type : Other Large Molecule

    Upfront Cash : Undisclosed

    July 11, 2023

    Lead Product(s) : Endoprotease 40 Glutenase

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase I

    Sponsor : European Union

    Deal Size : $2.7 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iron Hydroxide Adipate Tartrate

    Therapeutic Area : Hematology

    Study Phase : Approved FDF

    Sponsor : Bruno Farmaceutici

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Nemysis Limited Signs IHAT Sales and Marketing Agreement

    Details : Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.

    Product Name : IHAT

    Product Type : Vitamins/Minerals/Inorganic Salts

    Upfront Cash : Undisclosed

    May 07, 2023

    Lead Product(s) : Iron Hydroxide Adipate Tartrate

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Sponsor : Bruno Farmaceutici

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed

    Nemysis

    Ireland arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iron Hydroxide Adipate Tartrate

    Therapeutic Area : Hematology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First Chinese Patent for IHAT, the Novel Iron Nanoparticulate Supplement for Iron Deficiency (ID) and Iron Def...

    Details : The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.

    Product Name : IHAT-02

    Product Type : Vitamins/Minerals/Inorganic Salts

    Upfront Cash : Inapplicable

    December 05, 2021

    Lead Product(s) : Iron Hydroxide Adipate Tartrate

    Therapeutic Area : Hematology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth